Clinical Trial

An Exploratory Clinical Study of UX-DA001 in Subjects With Idiopathic Parkinson's Disease

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This clinical study is designed to explore the safety and tolerability of UX-DA001. It will also explore if UX-DA001 works to improve motor function in subjects with Parkinson's disease. UX-DA001 manufactured from participant's own cells will differentiate into mature dopaminergic neurons after being transplanted into the brain of the participant.
Protocol Amendment History 1 change
critical Trial status changed: Enrolling by Invitation → Active, Not Recruiting 2026-06-12
Trial Details
NCT Number NCT06778265
Lead Sponsor Shanghai UniXell Biotechnology Co., Ltd
Collaborators: Ruijin Hospital
Conditions Parkinson Disease, Idiopathic
Enrollment 12 participants
Start Date 2025-03-01
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-11